Melbourne, Australia and London, UK – October 13, 2022 ….. BioScience Managers, the international healthcare investment firm, is pleased to announce the appointment of David Atkins MBA PhD in the role of Managing Partner. Working alongside founder and Managing Partner, Jeremy Curnock Cook, David will be responsible for driving the future growth of BioScience Managers […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-10-13 08:56:042022-10-13 08:56:04BioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital Health
Melbourne, Australia – 21 September 2022 Link here : Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce the appointment of Mr Daniel Kaplon as Chief Financial Officer, effective 10 October 2022. Mr Rick Legleiter, Adherium Chief Executive Officer, commented, “we are very pleased to […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-09-21 07:56:472022-09-21 07:56:47Adherium appoints Daniel Kaplon as Chief Financial Officer
Melbourne, Australia – 20 September 2022 Link here : Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce a two-part clinical study at Washington University School of Medicine in St. Louis in the United States to monitor the adherence of Asthma patients using Adherium’s US […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-09-21 07:50:432022-09-21 07:50:43Clinical Study involving new Hailie Sensor with Physiological Parameters Launched in U.S.
Melbourne, Australia Link Here – 16 September 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, has secured subscription commitments from the Company’s Chairman, new and existing institutional and sophisticated investors, including cornerstone investments from existing shareholders Trudell Medical and BioScience Managers Translation Fund […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-09-20 07:10:202022-09-20 07:10:20Adherium secures A$13.5 million commitment in share and option placement
Melbourne, Australia Link Here – 13 September 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce a platform partnership with CareCentra Inc. to improve COPD (Chronic Obstructive Pulmonary Disease) and Asthma care by creating a truly transformative disease management suite. CareCentra will integrate Adherium’s […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-09-14 05:00:282022-09-14 05:00:28Adherium and CareCentra Team Up to Develop a Respiratory Risk Management System
Melbourne, Australia Link here – 9 September 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce a partnership agreement with Dulcian Health (“Dulcian”) to deploy the Hailie® platform enabling doctors and medical groups in the US to access reimbursement […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-09-09 02:55:012022-09-09 02:55:01Adherium agreement signed with Dulcian Health for US remote patient monitoring
Melbourne, Australia Link Here – 25 August 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of its 510(k) clearance to market application, which connects Teva ProAir® and Teva Albuterol Sulphate HFA metered […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-08-25 06:17:102022-08-25 06:17:10Adherium submits FDA 510(k) application for next generation Hailie sensor for Teva MDI inhalers
Melbourne, Australia / Link here – 16 August 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce its participation in the Reach Markets ‘Meet the CEOs’ live event, being held tomorrow, Wednesday 17th of August 2022. The webinar will open […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-08-16 01:27:142022-08-16 01:27:14Adherium to present at Reach Markets ‘Meet the CEOs’ live event
MARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]
Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., Aug. 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-08-10 04:48:492022-08-10 04:49:41CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)
BioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital Health
/in BioSciences ManagersMelbourne, Australia and London, UK – October 13, 2022 ….. BioScience Managers, the international healthcare investment firm, is pleased to announce the appointment of David Atkins MBA PhD in the role of Managing Partner. Working alongside founder and Managing Partner, Jeremy Curnock Cook, David will be responsible for driving the future growth of BioScience Managers […]
Adherium appoints Daniel Kaplon as Chief Financial Officer
/in AdheriumMelbourne, Australia – 21 September 2022 Link here : Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce the appointment of Mr Daniel Kaplon as Chief Financial Officer, effective 10 October 2022. Mr Rick Legleiter, Adherium Chief Executive Officer, commented, “we are very pleased to […]
Clinical Study involving new Hailie Sensor with Physiological Parameters Launched in U.S.
/in AdheriumMelbourne, Australia – 20 September 2022 Link here : Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce a two-part clinical study at Washington University School of Medicine in St. Louis in the United States to monitor the adherence of Asthma patients using Adherium’s US […]
Adherium secures A$13.5 million commitment in share and option placement
/in AdheriumMelbourne, Australia Link Here – 16 September 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, has secured subscription commitments from the Company’s Chairman, new and existing institutional and sophisticated investors, including cornerstone investments from existing shareholders Trudell Medical and BioScience Managers Translation Fund […]
Adherium and CareCentra Team Up to Develop a Respiratory Risk Management System
/in AdheriumMelbourne, Australia Link Here – 13 September 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce a platform partnership with CareCentra Inc. to improve COPD (Chronic Obstructive Pulmonary Disease) and Asthma care by creating a truly transformative disease management suite. CareCentra will integrate Adherium’s […]
Adherium agreement signed with Dulcian Health for US remote patient monitoring
/in AdheriumMelbourne, Australia Link here – 9 September 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce a partnership agreement with Dulcian Health (“Dulcian”) to deploy the Hailie® platform enabling doctors and medical groups in the US to access reimbursement […]
Adherium submits FDA 510(k) application for next generation Hailie sensor for Teva MDI inhalers
/in AdheriumMelbourne, Australia Link Here – 25 August 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of its 510(k) clearance to market application, which connects Teva ProAir® and Teva Albuterol Sulphate HFA metered […]
Adherium to present at Reach Markets ‘Meet the CEOs’ live event
/in AdheriumMelbourne, Australia / Link here – 16 August 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce its participation in the Reach Markets ‘Meet the CEOs’ live event, being held tomorrow, Wednesday 17th of August 2022. The webinar will open […]
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update
/in Armata PharmaceuticalsMARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]
CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)
/in CalcimedicaStudy provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., Aug. 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced […]